Welcome to our dedicated page for EVOMMUNE SEC filings (Ticker: EVMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evommune, Inc. (NYSE: EVMN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer. As a public company, Evommune submits reports to the U.S. Securities and Exchange Commission that describe its financial condition, clinical development progress and material corporate events.
Among these documents are current reports on Form 8-K, such as the filing in which Evommune reported issuing a press release with a business update and financial results for a completed quarter. That press release, furnished as an exhibit and incorporated by reference, summarized the status of its lead programs EVO756 and EVO301, clinical milestones, collaboration revenue and cash position. Similar filings can help readers understand how the company presents its pipeline and operations to regulators and investors.
On this page, users can review Evommune’s periodic and current reports, including items that address results of operations and financial condition, risk factor discussions and descriptions of forward-looking statements. These filings often elaborate on topics such as clinical trial design and timing, potential market opportunities for chronic inflammatory disease therapies, and risks related to regulatory approval, competition, intellectual property and collaborations.
Stock Titan enhances access to these SEC documents with AI-powered summaries that highlight key points from long filings, helping users quickly identify sections on clinical programs, financial metrics and material events. The page also updates as new filings are submitted to the SEC’s EDGAR system, allowing investors and researchers to follow Evommune’s regulatory history, including current reports, registration statements and other relevant disclosures.
Evommune, Inc. insider and 10% owner reports a share purchase. A reporting person who is both a director and 10% owner of Evommune, Inc. (EVMN) disclosed buying 1,000 shares of common stock on 12/19/2025 at a price of $17.35 per share through a family trust.
After this transaction, 4,026 shares of common stock are reported as indirectly owned through the family trust. Additional indirect holdings are reported as 1,441,032 shares through NFLS Delta III Limited, 1,632,441 shares through Pivotal bioVenture Partners Fund I, L.P., and 294,502 shares through Pivotal bioVenture Partners Fund II, L.P. In each case, the reporting person disclaims beneficial ownership beyond their proportionate pecuniary interest.
Evommune, Inc. reported an equity award to one of its senior leaders. On 12/08/2025, a reporting person who serves as both a director and Chief Medical Officer received an employee stock option to buy 100,000 shares of Evommune common stock at an exercise price of $18.44 per share. The option expires on 12/08/2035.
One fourth of the option shares will vest on December 8, 2026, and the remaining shares will vest in 36 equal monthly installments after that date, as long as the reporting person continues to provide service. After this grant, the reporting person beneficially owns 100,000 derivative securities directly.
Evommune, Inc. President and CEO, who is also a director, reported an automatic share withholding related to equity compensation. On 12/09/2025, 28,138 shares of Evommune common stock were disposed of at a reported price of $17.84 per share. The filing explains that these shares were withheld to cover the reporting person's tax withholding obligations upon the settlement of restricted stock units, rather than an open-market sale. After this tax withholding event, the reporting person beneficially owns 654,683 shares of Evommune common stock in direct ownership.
Evommune, Inc. reported an insider equity transaction by its Chief Scientific Officer, who is an officer of the company and files individually. On 12/09/2025, the officer had 7,513 shares of common stock withheld, coded as an "F" transaction, at a price of $17.84 per share. According to the explanation, these shares were withheld to cover the officer’s tax obligations arising from the settlement of restricted stock units, a common administrative step when stock awards vest.
After this tax withholding event, the officer beneficially owned 49,578 shares of Evommune common stock in direct ownership. The filing indicates this was not part of a trading plan under Rule 10b5-1, and does not involve any derivative securities such as options or warrants.
Evommune, Inc. executive Gregory S. Moss, the company’s Chief Business & Legal Officer, reported an insider transaction involving company stock. On 12/09/2025, 13,624 shares of Evommune common stock were withheld at a price of $17.84 per share to cover his tax withholding obligations tied to the settlement of restricted stock units. After this transaction, he directly beneficially owned 60,835 shares of common stock and indirectly held 3,175 additional shares through a family trust in which he serves as trustee.
Evommune, Inc. executive vice president of operations reported an insider equity transaction. On 12/09/2025, the officer had 5,074 shares of Evommune common stock withheld, coded as an "F" transaction, at a price of $17.84 per share. The filing explains these shares were withheld to satisfy tax withholding obligations tied to the settlement of restricted stock units, rather than being an open-market sale. After this tax-related transaction, the reporting person beneficially owned 67,794 shares of Evommune common stock directly.
Evommune, Inc. reported an insider equity transaction by its Chief Financial Officer on a Form 4. On 12/09/2025, 13,290 shares of common stock were withheld at a price of $17.84 per share to cover the officer’s tax obligations tied to the settlement of restricted stock units. After this tax withholding event, the CFO directly beneficially owned 62,510 shares of Evommune common stock.
Evommune, Inc. reported an insider equity transaction by a director and Chief Medical Officer. On 12/09/2025, the insider had 1,478 shares of common stock withheld at a price of $17.84 per share to cover tax withholding obligations tied to the settlement of restricted stock units. After this tax-related withholding, the insider beneficially owns 270,818 shares of Evommune common stock in direct ownership.
Evommune, Inc. reported its first meaningful collaboration revenue while remaining deeply loss-making as it advances inflammatory disease drug candidates EVO756 and EVO301. For the quarter ended September 30, 2025, license revenue was $10.0 million versus none a year earlier, driven mainly by a $10.0 million Maruho milestone, bringing year-to-date license revenue to $13.0 million compared with $7.0 million in 2024.
Total operating expenses rose to $23.3 million for the quarter and $64.4 million for the first nine months, led by research and development spending of $19.6 million in the quarter as clinical programs progressed. The company posted a quarterly net loss of $12.5 million and a nine‑month net loss of $40.6 million, with an accumulated deficit of $192.8 million.
Evommune strengthened its balance sheet with a $65.3 million Series C preferred financing in June 2025 and, after quarter‑end, a $172.5 million initial public offering in November 2025. As of September 30, 2025, it held $26.8 million in cash and cash equivalents and $49.2 million in short‑term investments, and management expects available capital to fund operations for at least twelve months from the financial statement issuance date.
Evommune, Inc. filed a current report to share that it has issued a press release with a business update and its financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference. The company notes that this information is being furnished rather than filed, which means it is not subject to certain liability provisions under the securities laws and is not automatically included in other SEC filings unless specifically referenced.